Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

111 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy.
Halabi S, Lin CY, Small EJ, Armstrong AJ, Kaplan EB, Petrylak D, Sternberg CN, Shen L, Oudard S, de Bono J, Sartor O. Halabi S, et al. Among authors: kaplan eb. J Natl Cancer Inst. 2013 Nov 20;105(22):1729-37. doi: 10.1093/jnci/djt280. Epub 2013 Oct 17. J Natl Cancer Inst. 2013. PMID: 24136890 Free PMC article. Clinical Trial.
A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006.
Picus J, Halabi S, Kelly WK, Vogelzang NJ, Whang YE, Kaplan EB, Stadler WM, Small EJ; Cancer and Leukemia Group B. Picus J, et al. Among authors: kaplan eb. Cancer. 2011 Feb 1;117(3):526-33. doi: 10.1002/cncr.25421. Epub 2010 Sep 22. Cancer. 2011. PMID: 20862750 Free PMC article. Clinical Trial.
111 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page